Autres langues BioXcel Therapeutics, Inc.

Actions

BTAI

US09075P1057

Temps réel estimé Cboe BZX Autres places de cotation 17:02:21 14/05/2024			Varia. 5j.	Varia. 1 janv.
2,225 ^USD	+1,83%		-4,68%	-24,07%

09/05	BioXcel Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/05	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
BioXcel Therapeutics Reports First Quarter 2024 Financial Results	09/05
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024	25/04
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting	24/04
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	22/04
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22/04
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22/04
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia	10/04
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	10/04
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	25/03
BioXcel Therapeutics Announces $25 Million Registered Direct Offering	25/03
50 valores para invertir en IA, salud, movilidad y energía	25/03
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	23/03
50 titoli per investire in AI, salute, mobilità ed energia	22/03
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	22/03
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	15/03
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	15/03
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	12/03
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023	12/03
North American Morning Briefing : Inflation Data -2-	12/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioXcel Therapeutics, Inc.

Actions

BTAI

US09075P1057

Autres langues

Filtres